Liquidia News

Liquidia Analyst Ratings

BenzingaJun 3 19:15

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaJun 3 19:17

Maintaining Buy Rating on Liquidia Technologies Amidst FDA Delay, Optimistic on Yutrepia's Market Potential

TipRanksMay 15 22:25

Liquidia Analyst Ratings

BenzingaMay 15 17:42

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaMay 15 17:43

Bullish Outlook for Liquidia Technologies With Buy Rating Amid Anticipated Patent Clarity and Market Growth Opportunities

TipRanksMay 15 03:35

Analysts Offer Insights on Healthcare Companies: Intellia Therapeutics (NTLA), Liquidia Technologies (LQDA) and Pacific Biosciences (PACB)

TipRanksMay 15 01:10

Buy Rating for Liquidia Technologies: Innovation and Market Potential Drive Strong Investment Case

TipRanksApr 10 18:55

Needham: Reiterates Liquidia's (LQDA.US) rating and adjusted from buy to buy rating, target price is $28.00.

Zhitong FinanceApr 10 19:01

Liquidia Analyst Ratings

BenzingaApr 10 18:58

Analysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Liquidia Technologies (LQDA) and Xtant Medical Holdings (XTNT)

TipRanksApr 2 17:11

Buy Rating Justified by Favorable Legal Outcomes and Imminent FDA Decision for Liquidia Technologies' Yutrepia

TipRanksApr 1 22:35

Liquidia Analyst Ratings

BenzingaApr 1 22:25

Needham Reiterates Buy on Liquidia, Maintains $28 Price Target

BenzingaApr 1 22:27

Liquidia Analyst Ratings

BenzingaMar 14 20:33

Liquidia Technologies Faces Sell Rating Amid Legal Struggles and Market Competition

TipRanksMar 14 22:25

Analysts Offer Insights on Healthcare Companies: Liquidia Technologies (LQDA) and Legend Biotech (LEGN)

TipRanksMar 14 18:10

Liquidia Analyst Ratings

BenzingaMar 14 04:08

Needham Maintains Buy on Liquidia, Maintains $28 Price Target

BenzingaMar 14 04:10

Buy Rating Affirmed for Liquidia Technologies Amid Favorable Legal Rulings and Yutrepia's Market Potential

TipRanksMar 14 02:55